Introduction
The difficulty in treating malignant brain tumors often derives from surgical limits and esistance to radiochemotherapy. Despite recent new anticancer agents, long term results of treatment for malignant brain tumors is still unsatisfactory (Takakura et al. 1986 ).
Antineoplastons are naturally occurring peptides and aminoacids which control neoplastic growth and were first described by Burzynski (1976 its effects were evaluated.
Patients and Methods
Patients in this study were 3 glioblastomas, 2 anaplastic astrocytomas, 1 pontine glioma, 2 metastatic brain tumors and 1 medulloblastoma.
All underwent radiochemotherapy (Table 1 ) and surgical resection of the tumors except for the pontine glioma (case 3), the metastatic brain tumors (case 7 and case 8) and one of the anaplastic astrocytomas (case 2) ( Table 2 ). All patients with gliomas were treated with remission maintenance therapy. The drug (1-(4-amino-2-methyl-pyridine-5-yl)-methyl-3-(2-chloroethyl-3-nitrosourea) (ACNU) or 1-
at intervals of several (Fig. 2) . Daily oral administration of Antineoplaston AS2-1 8.0 g/day was started on February, 1991 in addition to ACNU, MCNU once every 3 months and IFN once every 2 weeks, taken when he came to the hospital.
The neurological findings show no change since surgery over 3 years ago and no change in tumor size during this period on serial MRI has been noted (Fig. 3) .
Case 2
A 35-year-old male patient was admitted to Kurume University Hospital for nausea and general malaise on June 28, 1990. MRI on admission showed an isointensity mass lesion in the left thalamus (Fig. 4) . He underwent immediate V-P shunt and stereotaxic biopsy which spite of an initial regression of the tumor, confirmed by MRI, the tumor started growing soon and recurred in the original region. He was again admitted for chemotherapy (MCNU; 100 mg, AS2-1; 5-10 g/day) but died on April 6, 1992.
Discussion
The difficulty in treating malignant brain tumors is due mainly to the lim itaion of the amount of tissue that can be surgically excised, the low sensitivity to radiochemotherapy and the neurological symptoms which disturb patient rehabilitation (Takakura et al. 1986 ). The difficulty is greater when the tumor is only partially resected or when it recurs. High doses of chemotherapy and of irradiation may destroy life quality.
Chemotherapeutic agents without adverse effects may become available in the future. Burzynski (1976) proposed a biochemical defense mechanism which controls neoplastic growth by reprogramming of genes in addition to the immune system. He detected small peptides and aminoacid derivatives in human blood and urine working possibly under this mechanism and named them Antineoplaston. This Antineoplaston could be the ideal approach for maintenance therapy of malignant brain tumors. Antineoplaston A-10 is the first chemically identified and synthesized Antineoplaston found to be biologically active. A-10 is 3-phenylacetylamino-2,6-piperidinedione which is hydrolysed partially by pancreatic juice when administered orally with phenylacetylglutamine and phenylacetylisoglutamine at a ratio of 4:1. Antineoplaston AS2-1 is mixture of phenylacetylglutamine and phenyl acetic acid at a ratio of 1:4. Chemopreventive effects of A-10 toward various carcinogens such as Benzopyramine, Urethane, DMBA, AFB 1 and virus have been reported in many experimental animal models and Hendry et al. (1987) speculated that A-10 could be reversely intercalated between base pairs of DNA by stereospecific study. A-10 injection and AS2-1 inhibit neoplastic cell growth in many tumor cell lines but the mechanism of this action appears cytostatic. Lee (1991) showed an increase in NBT positive cells in the cultures of HL 60 cell line treated with A-10 and AS2-1. He also reported inhibition of glioma cell growth and decrease in G2, M phase cells by flowcytometry. Samid et al. (1991) stressed the antitumor effects of IFN a in combination with AS2-1 in A-375 malignant melanoma cells, PC-3 adenocarcinoma cells of the prostate and erythroleukemia cells. They found AS2-1 to induce cell differentiation, as shown by hemoglobin production in erythroleukemia cells. Tsuda et al. (1992) demonstrated in an electron microscopic study that A-10 injection in combination with small doses of CDDP induces morphological differentiation in human hepatocellular carcinoma. Liau et al. (1989) suggest that the hypomethylation of nucleic acids by AS2-1 may be essential for inducing cell differentiation. The competitive antagonism between 1-glutamine and phenylacetylglutamine is also proposed as a working mechanism since 1-glutamine is essential for cell growth. The antitumor effects of A-10 were also reported to appear slowly without obvious side effects. Nishida et al. (1991) demonstrate the decrease in the number of mitosis of A-10 treated tumors to be closely correlated to the reduction in tumor size in an in vivo study. Ram et al. (1994) reported AS2-1 to have potent cytostatic and antitumor effects in vitro and in vivo brain tumor models. The available data regarding the antitumor effect of Antineoplaston suggest that Antineoplaston works cytostatically and induce cell differentiation without severe side effects. The drug seems quite useful for maintenance chemotherapy of malignant brain tumors. Our clinical results showed CR 1/9 (11%), PR 2/9 (22%), NC 2/9 (22%), PG 4/9 (45%). The response is rather slow and long lasting. Case 1 was in stable conditions for years. Case 7 survived over 2 years. This study suggests usefulness of Antineoplaston in maintenance therapy of malignant brain tumors. The antitumor effects could be augmented by the combination of synchronization therapy (ACNU, Radiation, VCR, IFN) and Antineoplaston. Our result is only part of the phase 1 of a clinical study. Further multi-institutional study will evaluate the usefulness of Antineoplaston in malignant brain tumor therapy.
